←Tourette Syndrome
Study register · detail Retrospektive Fallserie · Tourette Syndrome · 2017

Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome.

Abi-Jaoude et al. ·Journal of Neuropsychiatry
Clear benefit GRADE Very low 60 citations
Samplen = 19 Pat.
EndpointTic score
Blindingn.a.
DesignRetrospektive Fallserie
Key finding

Cannabis reduced tic scores by 60% and led to marked clinical improvement in nearly all participants.

Summary

n=19 adults with Tourette syndrome; retrospective assessment of cannabis; tic scores reduced by 60%; 18 of 19 participants rated as at least "markedly improved". Cannabis generally well tolerated; most participants reported side effects.

P
PopulationAdults with Tourette syndrome, n=19
I
InterventionCannabis (substance, dose and route of administration not further specified)
O
OutcomeTic scores decreased by 60%; 18 of 19 participants showed at least 'marked improvement'
Confidence in the evidence
Very low

The lowest GRADE level, the effect estimate remains uncertain.

Downgraded for
Imprecision
Quality profile
Sample size ★★★★★
Blinding —
Effect size Clear benefit
Citations / year ★★★★★
Authors
Abi-Jaoude E, Chen L, Cheung P, Bhikram T, Sandor P.
DOI 10.1176/appi.neuropsych.16110310↗
Design: Retrospektive Fallserie
Share
Abstract
The authors retrospectively evaluated effectiveness and tolerability of cannabis in 19 adults with Tourette syndrome. Tics scores decreased by 60%, and 18 of the 19 participants were at least "much improved." Cannabis was generally well tolerated, although most participants reported side effects.
Indication
Further studies on Tourette Syndrome
All studies →
S Koppel et al. · 2014 · Neurology
545 citations
Systematic review: Efficacy and safety of medical Cannabis in selected neurologic disorders [RETIRED]
Mixed Systematische Review

AAN-Leitlinie (Guideline Development Subcommittee) — Systematische Review über k=34 Studien (davon 8 Class I) zu medizinischem Cannabis bei neurologischen Erkrankungen. Für Tourette-Syndrom: orale Cannabinoide von unbekannter Wirksamkeit (insufficient evidence). Risiko schwerer psychopathologischer Nebenwirkungen ~1%. [RETIRED-Status]

10.1212/wnl.0000000000000363 View study →
S Pringsheim et al. · 2019 · Neurology
249 citations
Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders.
Clear benefit Systematic Review

American Academy of Neurology Leitlinie basierend auf systematischer Review zu Tic-Behandlung bei Tourette-Syndrom. Hohe Konfidenz für Comprehensive Behavioral Intervention for Tics vs. Psychoedukation. Moderate Konfidenz für Haloperidol, Risperidon, Aripiprazol, Tiaprid, Clonidin, OnabotulinumtoxinA, 5-ling granule, Ningdong granule und Tiefenhirnstimulation des Globus pallidus zur Tic-Reduktion vs. Placebo. Niedrige Konfidenz (möglicherweise wirksam) für Pimozid, Ziprasidon, Metoclopramid, Guanfacin, Topiramat und Tetrahydrocannabinol. Evidenz für verschiedene Nebenwirkungen (Gewichtszunahme, medikamenteninduzierte Bewegungsstörungen, erhöhte Prolaktinspiegel, Sedierung, kardiovaskuläre Effekte).

10.1212/wnl.0000000000007467 View study →
A Rice et al. · 2024 · European child & adolescent psychiatry
24 citations
Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.
No benefit demonstrated Systematic Review

Systematische Review zu Cannabinoiden bei neuro­psychiatrischen und neuro­entwicklungs­bedingten Störungen bei Kindern/Jugendlichen (≤18 Jahre); k=18 eingeschlossene Artikel zu 8 Störungsbildern, davon n=3 zu Tourette-Syndrom. Nur 1 RCT identifiziert; Rest: 1 Open-Label-Studie, 3 unkontrollierte Vorher-Nachher-Studien, 2 Fallserien, 11 Fallberichte — hohes Bias-Risiko. Schlussfolgerung: limitierte und generell schlechte Evidenzqualität für Cannabinoid-Wirksamkeit.

10.1007/s00787-023-02169-w View study →

The impediment to action advances action. — Marcus Aurelius